Even though the number of patients with metastatic CCRCC in this series is small, we can confirm that PD-L1 expression in tumor center is higher in metastatic patients within the IMDC poor prognosis group (p = 0.056) and also that sPD-L1 levels better discriminate poor prognosis for this population of (p = 0.021). The gene discussed is SPDL1; the disease is neoplasm.